Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13985605 | 1.00 | MAPT (0.50) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL13059798 | 1.00 | MAPT (0.50) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL4072294 | 0.88 | MAPT (0.50) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL3538785 | 0.88 | MAPT (0.50) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL3535329 | 0.88 | MAPT (0.50) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL3540797 | 0.88 | MAPT (0.50) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL3536137 | 0.88 | MAPT (0.50) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL2795742 | 0.87 | MAPT (0.52) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL2795738 | 0.87 | MAPT (0.52) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL22034017 | 0.87 | MAPT (0.52) | MAPTPDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445480-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARP & DOHME CORP. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100298288-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298288-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | CETP, APOB, MTTP | MAPT 2099/4885PDK1 3097/4885PDK2 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.